Toward responsible clinical n-of-1 strategies for rare diseases

Area of Science:

• Medical research methodology
• Clinical trial design
• Evidence-based medicine

Background:

• N-of-1 strategies provide individual-level evidence for treatment efficacy.
• These strategies are valuable for optimizing off-label treatment selection in rare diseases.
• N-of-1 strategies bridge medical research and clinical care, leading to regulatory debate.

Purpose of the Study:

• To delineate the differences between medical research and optimized clinical care.
• To distinguish the regulations applicable to research versus clinical care.
• To establish standards for responsible, optimized clinical n-of-1 strategies for rare diseases.

Main Methods:

• Comparative analysis of research and clinical care frameworks.
• Review of existing regulatory guidelines for medical research and patient care.
• Development of a framework for clinical n-of-1 strategy implementation.

Main Results:

• Clear distinctions were drawn between research-driven and care-driven approaches.
• Specific regulatory considerations for each approach were identified.
• Standards for responsible clinical n-of-1 strategies were proposed.

Conclusions:

• Implementing defined clinical n-of-1 strategies can optimize treatment selection for rare diseases.
• Clarifying regulatory pathways is crucial for the responsible use of n-of-1 trials in clinical practice.
• This work provides a foundation for integrating n-of-1 strategies into routine care for rare conditions.